In a bid to bolster its oncology pipeline, AbbVie has entered into a collaboration and option-to-license agreement with Xilio Therapeutics to develop tumour-activated, antibody-based immunotherapies, including masked T-cell engagers. The deal, which is worth up to US$2.1 B, aims to combine Xilio's immuno-oncology platform technology with AbbVie's expertise in oncology, with the goal of delivering more effective and targeted cancer therapies for patients. As its blockbuster biologic Humira continues to face generic erosion, the deal marks yet another move by AbbVie to bolster its oncology pipeline and secure its future revenue.